Drugs / Inzomelid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04338997 | Oct → Nov 2020 | Parkinson disease | Inflazome UK Ltd | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04015076 | Jul 2019 → Mar 2020 | — | Inflazome UK Ltd | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inzomelid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04015076 ↗ |
| Known as | Emlenoflast | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650350 ↗ |
| Known as | IZD174 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04338997 ↗ |
| Known as | MCC-7840 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650350 ↗ |
| Action | Inhibit | “Small molecule inhibitor of NLRP3” NCT04338997 ↗ |
| Modality | Small molecule | “Small molecule inhibitor of NLRP3” NCT04338997 ↗ |
| Route | Oral | “Oral IZD174” NCT04338997 ↗ |
| Target | NLRP3 | “Small molecule inhibitor of NLRP3” NCT04338997 ↗ |